BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 23233126)

  • 1. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
    Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
    Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells.
    Liu YM; Li XF; Liu H; Wu XL
    Oncol Rep; 2015 Dec; 34(6):2977-86. PubMed ID: 26370320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
    Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
    Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
    Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
    Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
    Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
    Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
    Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
    Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy.
    Li J; Chen JN; Zeng TT; He F; Chen SP; Ma S; Bi J; Zhu XF; Guan XY
    BMC Cancer; 2016 Jan; 16():15. PubMed ID: 26758620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lentivirus-mediated RNA interference of CD133 inhibits the proliferation of CD133(+) liver cancer stem cells and increases their cisplatin chemosensitivity].
    Lan X; Wang Y; Cao S; Zou D; Li F; Li S
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Dec; 32(12):1741-7. PubMed ID: 23268401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α.
    Lee JH; Hur W; Hong SW; Kim JH; Kim SM; Lee EB; Yoon SK
    Oncol Rep; 2017 Feb; 37(2):813-822. PubMed ID: 27959451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of β-catenin.
    Quan MF; Xiao LH; Liu ZH; Guo H; Ren KQ; Liu F; Cao JG; Deng XY
    World J Gastroenterol; 2013; 19(43):7680-95. PubMed ID: 24431896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells.
    Wang R; Sun Q; Wang P; Liu M; Xiong S; Luo J; Huang H; Du Q; Geller DA; Cheng B
    Oncotarget; 2016 Feb; 7(5):5754-68. PubMed ID: 26735577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations.
    Yang Z; Zhang L; Ma A; Liu L; Li J; Gu J; Liu Y
    PLoS One; 2011; 6(12):e28405. PubMed ID: 22145042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma.
    Piao LS; Hur W; Kim TK; Hong SW; Kim SW; Choi JE; Sung PS; Song MJ; Lee BC; Hwang D; Yoon SK
    Cancer Lett; 2012 Feb; 315(2):129-37. PubMed ID: 22079466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring stemness gene expression and vasculogenic mimicry capacity in well- and poorly-differentiated hepatocellular carcinoma cell lines.
    Lirdprapamongkol K; Chiablaem K; Sila-Asna M; Surarit R; Bunyaratvej A; Svasti J
    Biochem Biophys Res Commun; 2012 Jun; 422(3):429-35. PubMed ID: 22580004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenite inhibits the function of CD133
    Tang H; Jin Y; Jin S; Tan Z; Peng Z; Kuang Y
    Tumour Biol; 2016 Oct; 37(10):14103-14115. PubMed ID: 27517564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells.
    Jia Q; Zhang X; Deng T; Gao J
    Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
    Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
    Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 8-bromo-5-hydroxy-7-methoxychrysin targeting for inhibition of the properties of liver cancer stem cells by modulation of Twist signaling.
    Ren KQ; Cao XZ; Liu ZH; Guo H; Quan MF; Liu F; Jiang L; Xiang HL; Deng XY; Cao JG
    Int J Oncol; 2013 Nov; 43(5):1719-29. PubMed ID: 23970349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment.
    Song YJ; Zhang SS; Guo XL; Sun K; Han ZP; Li R; Zhao QD; Deng WJ; Xie XQ; Zhang JW; Wu MC; Wei LX
    Cancer Lett; 2013 Oct; 339(1):70-81. PubMed ID: 23879969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced tumorigenesis and lymphatic metastasis of CD133+ hepatocarcinoma ascites syngeneic cell lines mediated by JNK signaling pathway in vitro and in vivo.
    Jin Y; Mao J; Wang H; Hou Z; Ma W; Zhang J; Wang B; Huang Y; Zang S; Tang J; Li L
    Biomed Pharmacother; 2013 May; 67(4):337-45. PubMed ID: 23582787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.